Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period)Previous forecast published 5 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Domestic sales of blood collection tube preparation equipment and systems, as well as specimen testing equipment, remained solid, while selling, general and administrative expenses decreased because some of the research and development expenses planned for the first half were capitalized as fixed assets.
| Item | Details |
|---|---|
| Net Sales | ¥4,360 million → ¥4,453 million（+2.1%） |
| Operating profit | ¥300 million → ¥468 million（+56.1%） |
| Ordinary income | ¥310 million → ¥485 million（+56.7%） |
| Profit attributable to owners of the parent | ¥220 million → ¥321 million（+46.0%） |
| Net income per share | ¥31.9 yen → ¥48.94 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 5 August 2026 |
| Previous-period results | Net Sales 4,104 / Operating profit 266 / Ordinary income 294 / Interim net income 203 / Interim net profit per share 29.31 / Fiscal Period Covered Second quarter of the fiscal year ended March 2026 |
| Reason for the revision | Domestic sales of blood collection tube preparation equipment and systems, as well as specimen testing equipment, remained solid, while selling, general and administrative expenses decreased because some of the research and development expenses planned for the first half were capitalized as fixed assets. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue exceeded the forecast because domestic sales of blood collection tube preparation equipment and systems, as well as specimen testing equipment, remained solid. In addition, some of the research and development expenses planned for the first half were capitalized as fixed assets, reducing selling, general and administrative expenses. As a result, operating income, ordinary income and interim net income exceeded the forecast.